Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutics International, a multinational contract formulation development and commercial manufacturing company, and NexMed, a pharmaceutical and medical technology company, have signed a memorandum of understanding for a strategic product development collaboration utilizing NexMed's NexACT drug delivery platform.
Subscribe to our email newsletter
Pursuant to the memorandum of understanding (MoU), Pharmaceutics International (PII) will promote the NexACT technology to its clients and may independently identify new product development opportunities for this collaboration with NexMed.
PII will be responsible for the R&D of the new pharmaceutical products with technical guidance and oversight from NexMed, and will also assume responsibility for clinical trial material manufacturing and commercial manufacturing of the new products.
Hem Pandya, COO of NexMed, said: “We are very pleased to enter into this collaboration with PII. The strategic goal is to broaden the promotion of our technology and permit us access to PII’s R&D and commercial manufacturing infrastructure. We will also be able to continue with our current product development efforts at significantly reduced monthly overhead expenses.”